United Therapeutics
Open
$548.29
Prev. Close
$547.59
High
$549.36
Low
$547.96
Market Snapshot
$24.03B
18.7
26.42
$2.88B
United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. The company is headquartered in Silver Spring, Maryland and currently employs 1,400 full-time employees. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. The company is headquartered in Silver Spring, Maryland and currently employs 1,400 full-time employees. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
Recently from Cashu
United Therapeutics Achieves Phase 3 Success for Pulmonary Disease Drug and Innovates with Space Partnership
United Therapeutics (Ticker: UTHR) has achieved a major milestone in its efforts to combat pulmonary diseases with the successful results from its TETON-1 phase 3 study. This trial focused on nebulize…
United Therapeutics Advances Pulmonary Disease Treatment with TETON-1 Trial Success and Space Partnership
United Therapeutics (Ticker: UTHR) is at the forefront of innovation in the treatment of pulmonary diseases, with recent successes in clinical research significantly enhancing its profile in the bioph…
United Therapeutics Advances Innovative Treatments and Organ Transplant Technologies in Biotech Sector
United Therapeutics (Ticker: UTHR) continues to make waves in the biotechnology sector with its innovative approach to treating pulmonary arterial hypertension (PAH) and advancing organ transplantatio…
United Therapeutics to Present Phase 3 Data on Tyvaso and Ralinepag at Conference
United Therapeutics (Ticker: UTHR) prepares to present new phase 3 clinical trial data for Tyvaso, an inhaled form of treprostinil aimed at treating idiopathic pulmonary fibrosis (IPF). The company al…